Floatz logo

tt-4

Hepatocellular Carcinoma

Tarus Therapeutics, Inc.Phase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

520 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Theprubicin
RWTH Aachen University
Phase 4BB
nrt6003
Second Affiliated Hospital of Guangzhou Medical University
Phase 3BB
Inno-206
VA Office of Research and Development
Phase 4BB

View all 50 →

Same molecule, other indications

tt-4 is also rated in:

castration-resistant prostate carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →